Pharmaceutical giant to pay fines
21-06-2003
Astra Zeneca Pharmaceutical company agreed to pay fines totalling 355 million $ to settle charges over illegal sales practices, which include overcharging for its prostate cancer drug Zoladex and bribing doctors to prescribe the drug, reports an article in the Boston Globe today.Such practices apparently are not an exception but rather seem to be the rule. In a separate case Astra Zeneca's competitor TAP pharmaceuticals paid an even larger amount two years ago to settle similar allegations made against it in a case in Boston.
''Like the TAP case, it's going to send the message to the drug industry that they should be marketing the drug based on what's best for the patient rather than how much profit the doctor will be making,'' said Beth Moskow-Schnoll, the assistant US attorney who prosecuted the case. ''Everything they did was based on corporate greed. The Medicare system shouldn't be used to put profit into doctor's pockets.''
Drug firm agrees to big penalty
AstraZeneca will pay $355m to settle drug fraud charges
By Alice Dembner, Globe Staff, 6/21/2003
Drug maker AstraZeneca agreed to the second largest settlement for alleged drug fraud in US history yesterday, paying $355 million to resolve criminal and civil allegations that the company inflated the price of its prostate cancer drug and bribed doctors to prescribe it.
The settlement, announced by federal prosecutors in Delaware, is second only to the record $885 million paid by TAP Pharmaceutical Products in 2001 to settle similar allegations in a Boston case. During the 1990s, the two companies battled to gain sales for their competing prostate cancer drugs, using tactics that included leveraging federal money to provide kickbacks to doctors.
''Like the TAP case, it's going to send the message to the drug industry that they should be marketing the drug based on what's best for the patient rather than how much profit the doctor will be making,'' said Beth Moskow-Schnoll, the assistant US attorney who prosecuted the case. ''Everything they did was based on corporate greed. The Medicare system shouldn't be used to put profit into doctor's pockets.''
AstraZeneca, whose US headquarters are in Delaware, pleaded guilty yesterday to criminally defrauding the government of more than $39 million by providing doctors across the country with thousands of free samples of Zoladex, knowing that the doctors would bill government insurance programs as much as $300 for each sample. The company will pay a criminal fine of $63.8 million.
The settlement also includes $291 million to settle civil allegations that the company denies. Prosecutors alleged the London-based company deliberately inflated the price paid by the government for every dose of Zoladex, that it provided doctors with grants, trips, and speaking fees to induce them to prescribe the drug, and that it defrauded state Medicaid programs by failing to give them the lowest price charged any customer for the drug.
''We did today plead guilty to conspiracy to violate the Prescription Drug Marketing Act,'' said company spokeswoman Rachel Bloom-Baglin. ''We are accepting responsibility and regret that those activities did occur. However, AstraZeneca believes that our pricing for Zoladex was at all times lawful.''
As in the TAP case, the government alleged that AstraZeneca had persuaded doctors to prescribe Zoladex by showing them that they could make a profit on each dose, not only by selling free samples, but by charging the government far more for the drugs than they paid to purchase them. The drugs, administered by injection in a doctor's office, are among the few now reimbursed through the Medicare program.
''They were in a competition to see who could cheat the most and drive the price up the highest to get the doctors to use their drug,'' said James Moorman, executive director of Taxpayers Against Fraud, a Washington-based group that aids whistle-blowers. ''Cheating didn't just get them more money, it got them more market share. The good news is it's going to stop, or they're going to pay an enormous price.''
Although prosecutors in Boston are pressing criminal charges against TAP officials, Moskow-Schnoll in Delaware said there would be no prosecution of AstraZeneca officials because investigators could find no evidence that the actions were sanctioned by top management. She said the investigation will continue into doctors across the country who benefited from the fraud. Two doctors have already pleaded guilty to conspiracy charges and a third was charged last month.
The company has agreed to cooperate in those investigations and to promote ethical and legal sales and marketing practices.
The case began in 1996 when a TAP sales vice president quit his job and blew the whistle on practices he considered unethical at both TAP and rival AstraZeneca. For alerting prosecutors to the fraud, Douglas Durand will receive a reward of $47.5 million in the AstraZeneca case on top of the $78 million he got in the TAP case. Durand, 51, has retired in Florida and is using some of the money to support cancer research, according to his lawyer Elizabeth Ainslie.
Article published in the Boston Globe
Alice Dembner can be reached at Dembner@globe.com.
Here's the same story with some more detail, written by Melody Petersen in New York Times
posted by Sepp Hasslberger on Saturday June 21 2003
updated on Tuesday December 4 2007URL of this article:
http://www.newmediaexplorer.org/sepp/2003/06/21/pharmaceutical_giant_to_pay_fines.htm
Related ArticlesUS Health System Needs Radical Overhaul: New York Times
25 October 2004 - In last Sunday's New York Times, editors Donald Barlett and James Steele called for a radical overhaul of the US health system. While the calamitous failure of pharmaceutical suppliers to come up with a sufficient quantity of flu vaccine provides the immediate backdrop for the article, the discussion goes much deeper. It is really about why the US health system has dismally failed to deliver on... [read more]
October 25, 2004 - Sepp HasslbergerPharma profits do not equal health - Berkely Prof advocates alternative
As reported in BBC News today, Nobel-prize winner and Berkely Prof Sydney Brenner, an expert on molecular biology, said people should be told to look after their health instead of expecting science to "come to their rescue with a pill". "There are two kinds of health care. There's taking care of the health of the public and there's taking care of the financial health of the drug companies," added Brenner.... [read more]
September 03, 2003 - Sepp HasslbergerMedical system is leading cause of death and injury in US
Shocking statistical evidence is cited by Gary Null PhD, Caroly Dean MD ND, Martin Feldman MD, Debora Rasio MD and Dorothy Smith PhD in their recent paper Death by Medicine - October 2003, released by the Nutrition Institute of America. "A definitive review and close reading of medical peer-review journals, and government health statistics shows that American medicine frequently causes more harm than good. The number of people having in-hospital,... [read more]
October 29, 2003 - Sepp HasslbergerPharma makers withhold suicide data in drug studies
According to an article in the Washington Post, the makers of popular antidepressants such as Paxil, Zoloft and Effexor have refused to disclose the details of most clinical trials involving depressed children, denying doctors and parents crucial evidence as they weigh fresh fears that such medicines may cause some children to become suicidal. Apparently the drug makers are free to keep data hidden contravening, if not the letter of the... [read more]
February 02, 2004 - Sepp HasslbergerInvestigator Exposes Pharma Corruption - Loses Job
An investigator with the Pennsylvania Office of the Inspector General was removed from his post and sent home after he talked to the press about his discovery of a black bank account fed by pharma companies Janssen and Pfizer and apparently used to pay off FDA officials in charge of approving drugs. The story is reported in the British Medical Journal.... [read more]
May 15, 2004 - Sepp HasslbergerPharma Promotion Dishonest - Slanted Reporting of Paxil, Prozac Studies
Pharmaceutical manufacturers cannot promote the use of drugs for other uses than those approved for the label, however it has become normal practice to dishonestly slant the reporting of scientific studies to suggest such unapproved use of drugs or to hype the supposed benefits of certain medicines, while hiding their adverse effects. GlaxoSmithKline, the manufacturer of the antidepressant Paxil, released on its company Web site the reports of clinical tests... [read more]
June 15, 2004 - Sepp Hasslberger
